Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma
Authors:
- M. A. MingalimovMMM. A. Mingalimov
- E. A. BaryakEBE. A. Baryak
- A. V. MisyurinAMA. V. Misyurin
- L. A. KesaevaLKL. A. Kesaeva
- A. S. MkrtchyanAMA. S. Mkrtchyan
- E. N. MisyurinaEME. N. Misyurina
- M. A. DonskoyMDM. A. Donskoy
- T. N. TolstykhTTT. N. Tolstykh
- M. S. OrlovaMOM. S. Orlova
- T. S. ChudnovaTCT. S. Chudnova
- D. D. IvanovaDID. D. Ivanova
- O. L. KochnevaOKO. L. Kochneva
Open Access
- 11 September 2025
- journal article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (3) , 22-26
Abstract
Background. Despite tremendous progress in understanding tumor biology, the R-CHOP protocol remains the standard of care for diffuse large B-cell lymphoma (DLBCL). To date, six genetic variants of DLBCL have been identified, the most unfavorable of which when using standard therapy are N1, MCD and BN2, which dictates the need to optimize the treatment of these DLBCL subtypes.Aim. To evaluate the efficacy and toxicity of Acala-R-CHOP regimen in induction therapy in patients with newly diagnosed DLBCL.Materials and methods. The study included 15 patients who received Acala-R-CHOP program as part of the first-line therapy. This antitumor regimen was used for verified genotypes N1, MCD and BN2. The median age was 64 (38–78) years. The incidence of genetic variants in the considered cohort of patients: MCD – 13 % (n = 2), N1 – 74 % (n = 11), BN2 – 13 % (n = 2).Results. Fifteen patients completed the therapy. The overall and complete metabolic response rates were 100 %. Toxicity was moderate, quite manageable and manifested mainly as myelosuppression.Conclusion. The efficacy of Acala-R-CHOP therapy in patients with MCD, N1, and BN2 DLBCL genotypes is high with a low toxicity profile. However, longer follow-up periods are needed to assess the long-term results in this unfavorable group of patients.Keywords
This publication has 13 references indexed in Scilit:
- Biological heterogeneity in diffuse large B-cell lymphomaSeminars in Hematology, 2023
- Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trialCancer Cell, 2023
- Molecular classification and therapeutics in diffuse large B-cell lymphomaFrontiers in Molecular Biosciences, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsLeukemia, 2022
- Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CTBlood Research, 2022
- Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCLCancer Cell, 2021
- Application of the LymphGen classification tool to 928 clinically and genetically‐characterised cases of diffuse large B cell lymphoma (DLBCL)British Journal of Haematology, 2020
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid MalignanciesCells, 2018
- Diffuse large B-cell lymphoma: R-CHOP failure—what to do?Hematology-American Society Hematology Education Program, 2016